974 related articles for article (PubMed ID: 34535562)
21. Targeting ACC for NASH resolution.
Zhang XJ; Cai J; Li H
Trends Mol Med; 2022 Jan; 28(1):5-7. PubMed ID: 34844875
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
Morrow MR; Batchuluun B; Wu J; Ahmadi E; Leroux JM; Mohammadi-Shemirani P; Desjardins EM; Wang Z; Tsakiridis EE; Lavoie DCT; Reihani A; Smith BK; Kwiecien JM; Lally JSV; Nero TL; Parker MW; Ask K; Scott JW; Jiang L; Paré G; Pinkosky SL; Steinberg GR
Cell Metab; 2022 Jun; 34(6):919-936.e8. PubMed ID: 35675800
[TBL] [Abstract][Full Text] [Related]
23. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
24. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
25. Malonylation of Acetyl-CoA carboxylase 1 promotes hepatic steatosis and is attenuated by ketogenic diet in NAFLD.
Cao H; Cai Q; Guo W; Su Q; Qin H; Wang T; Xian Y; Zeng L; Cai M; Guan H; Chen S; Liang H; Xu F
Cell Rep; 2023 Apr; 42(4):112319. PubMed ID: 37002924
[TBL] [Abstract][Full Text] [Related]
26. Anti-hepatic steatosis activity of Sicyos angulatus extract in high-fat diet-fed mice and chemical profiling study using UHPLC-qTOF-MS/MS spectrometry.
An JP; Choi JH; Huh J; Lee HJ; Han S; Noh JR; Kim YH; Lee CH; Oh WK
Phytomedicine; 2019 Oct; 63():152999. PubMed ID: 31280138
[TBL] [Abstract][Full Text] [Related]
27. Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Huard K; Smith AC; Cappon G; Dow RL; Edmonds DJ; El-Kattan A; Esler WP; Fernando DP; Griffith DA; Kalgutkar AS; Ross TT; Bagley SW; Beebe D; Bi YA; Cabral S; Crowley C; Doran SD; Dowling MS; Liras S; Mascitti V; Niosi M; Pfefferkorn JA; Polivkova J; Préville C; Price DA; Shavnya A; Shirai N; Smith AH; Southers JR; Tess DA; Thuma BA; Varma MV; Yang X
J Med Chem; 2020 Oct; 63(19):10879-10896. PubMed ID: 32809824
[TBL] [Abstract][Full Text] [Related]
28. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK
J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205
[TBL] [Abstract][Full Text] [Related]
29. The L-α-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis.
Fondevila MF; Fernandez U; Gonzalez-Rellan MJ; Da Silva Lima N; Buque X; Gonzalez-Rodriguez A; Alonso C; Iruarrizaga-Lejarreta M; Delgado TC; Varela-Rey M; Senra A; Garcia-Outeiral V; Novoa E; Iglesias C; Porteiro B; Beiroa D; Folgueira C; Tojo M; Torres JL; Hernández-Cosido L; Blanco Ó; Arab JP; Barrera F; Guallar D; Fidalgo M; López M; Dieguez C; Marcos M; Martinez-Chantar ML; Arrese M; Garcia-Monzon C; Mato JM; Aspichueta P; Nogueiras R
Hepatology; 2021 Feb; 73(2):606-624. PubMed ID: 32329085
[TBL] [Abstract][Full Text] [Related]
30. A novel inhibitor of stearoyl-CoA desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis.
Kurikawa N; Takagi T; Wakimoto S; Uto Y; Terashima H; Kono K; Ogata T; Ohsumi J
Biol Pharm Bull; 2013; 36(2):259-67. PubMed ID: 23370355
[TBL] [Abstract][Full Text] [Related]
31. Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions.
Abu-Elheiga L; Wu H; Gu Z; Bressler R; Wakil SJ
J Biol Chem; 2012 Apr; 287(15):12578-88. PubMed ID: 22362781
[TBL] [Abstract][Full Text] [Related]
32. A bacteria-derived tetramerized protein ameliorates nonalcoholic steatohepatitis in mice via binding and relocating acetyl-coA carboxylase.
Lin Y; Yang M; Huang L; Yang F; Fan J; Qiang Y; Chang Y; Zhou W; Yan L; Xiong J; Ping J; Chen S; Men D; Li F
Cell Rep; 2023 Nov; 42(11):113453. PubMed ID: 37976162
[TBL] [Abstract][Full Text] [Related]
33. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
Harriman G; Greenwood J; Bhat S; Huang X; Wang R; Paul D; Tong L; Saha AK; Westlin WF; Kapeller R; Harwood HJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1796-805. PubMed ID: 26976583
[TBL] [Abstract][Full Text] [Related]
34. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway.
Fondevila MF; Novoa E; Gonzalez-Rellan MJ; Fernandez U; Heras V; Porteiro B; Parracho T; Dorta V; Riobello C; da Silva Lima N; Seoane S; Garcia-Vence M; Chantada-Vazquez MP; Bravo SB; Senra A; Leiva M; Marcos M; Sabio G; Perez-Fernandez R; Dieguez C; Prevot V; Schwaninger M; Woodhoo A; Martinez-Chantar ML; Schwabe R; Cubero FJ; Varela-Rey M; Crespo J; Iruzubieta P; Nogueiras R
Cell Rep Med; 2024 Feb; 5(2):101401. PubMed ID: 38340725
[TBL] [Abstract][Full Text] [Related]
35. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
36. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.
Harwood HJ; Petras SF; Shelly LD; Zaccaro LM; Perry DA; Makowski MR; Hargrove DM; Martin KA; Tracey WR; Chapman JG; Magee WP; Dalvie DK; Soliman VF; Martin WH; Mularski CJ; Eisenbeis SA
J Biol Chem; 2003 Sep; 278(39):37099-111. PubMed ID: 12842871
[TBL] [Abstract][Full Text] [Related]
37. Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH.
Lu Y; Su X; Zhao M; Zhang Q; Liu C; Lai Q; Wu S; Fang A; Yang J; Chen X; Yao Y
PeerJ; 2019; 7():e8115. PubMed ID: 31879571
[TBL] [Abstract][Full Text] [Related]
38. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
39. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease.
Park H; Liu Y; Kim HS; Shin JH
Nutr Res; 2016 Jan; 36(1):57-64. PubMed ID: 26773781
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
Li H; Ying H; Hu A; Hu Y; Li D
Biol Pharm Bull; 2017; 40(5):650-657. PubMed ID: 28458350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
